Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Buti

Showing results (221-230 of 386) with videos related to

Pageof 39
Sort By:
Plos One|June 6, 2012
Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genomeFrancisco Rodriguez-Frías, David Tabernero, Josep Quer, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 29, 2019
Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infectionPatrick Marcellin, David K Wong, William Sievert, et al.
Lancet (London, England)|June 8, 2014
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trialMichael Manns, Patrick Marcellin, Fred Poordad, et al.
Journal of Hepatology|May 16, 2026
siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flaresHeiner Wedemeyer, Ed Gane, Kosh Agarwal, et al.
Clinical and Experimental Gastroenterology|December 7, 2016
HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infectionChristoph Sarrazin, Francesco Castelli, Pietro Andreone, et al.
JHEP Reports : Innovation in Hepatology|March 13, 2023
Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cellsAbhishek Aggarwal, Pamela M Odorizzi, Jens Brodbeck, et al.
Journal of Hepatology|May 20, 2018
Erratum to "A new HDV mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN-β induction" [J Hepatol 67 (2017) 669-679]Lester Suárez-Amarán, Carla Usai, Marianna Di Scala, et al.
Journal of Hepatology|April 16, 2019
Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacyCihan Yurdaydin, Zaigham Abbas, Maria Buti, et al.
Lancet (London, England)|December 14, 2012
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up studyPatrick Marcellin, Edward Gane, Maria Buti, et al.
European Journal of Epidemiology|June 26, 2023
Genome-wide epistasis study highlights genetic interactions influencing severity of COVID-19Shiqi Lin, Xingjian Gao, Frauke Degenhardt, et al.
Pageof 39

Showing results (221-230 of 386) with videos related to

Sort By:
Pageof 39
Plos One|June 6, 2012
Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genomeFrancisco Rodriguez-Frías, David Tabernero, Josep Quer, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 29, 2019
Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infectionPatrick Marcellin, David K Wong, William Sievert, et al.
Lancet (London, England)|June 8, 2014
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trialMichael Manns, Patrick Marcellin, Fred Poordad, et al.
Journal of Hepatology|May 16, 2026
siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flaresHeiner Wedemeyer, Ed Gane, Kosh Agarwal, et al.
Clinical and Experimental Gastroenterology|December 7, 2016
HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infectionChristoph Sarrazin, Francesco Castelli, Pietro Andreone, et al.
JHEP Reports : Innovation in Hepatology|March 13, 2023
Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cellsAbhishek Aggarwal, Pamela M Odorizzi, Jens Brodbeck, et al.
Journal of Hepatology|May 20, 2018
Erratum to "A new HDV mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN-β induction" [J Hepatol 67 (2017) 669-679]Lester Suárez-Amarán, Carla Usai, Marianna Di Scala, et al.
Journal of Hepatology|April 16, 2019
Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacyCihan Yurdaydin, Zaigham Abbas, Maria Buti, et al.
Lancet (London, England)|December 14, 2012
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up studyPatrick Marcellin, Edward Gane, Maria Buti, et al.
European Journal of Epidemiology|June 26, 2023
Genome-wide epistasis study highlights genetic interactions influencing severity of COVID-19Shiqi Lin, Xingjian Gao, Frauke Degenhardt, et al.
Pageof 39